PortalPublikationenClinical Relevance of Circulating Tumor Cells in Esophageal ...

Clinical Relevance of Circulating Tumor Cells in Esophageal Cancer Detected by a Combined MACS Enrichment Method

Standard

Clinical Relevance of Circulating Tumor Cells in Esophageal Cancer Detected by a Combined MACS Enrichment Method. / Woestemeier, Anna; Harms-Effenberger, Katharina; Karstens, Karl-F; Konczalla, Leonie; Ghadban, Tarik; Uzunoglu, Faik G; Izbicki, Jakob R; Bockhorn, Maximilian; Pantel, Klaus; Reeh, Matthias.

in: CANCERS, Jahrgang 12, Nr. 3, 18.03.2020, S. 718.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Woestemeier, A, Harms-Effenberger, K, Karstens, K-F, Konczalla, L, Ghadban, T, Uzunoglu, FG, Izbicki, JR, Bockhorn, M, Pantel, K & Reeh, M 2020, 'Clinical Relevance of Circulating Tumor Cells in Esophageal Cancer Detected by a Combined MACS Enrichment Method', CANCERS, Jg. 12, Nr. 3, S. 718. https://doi.org/10.3390/cancers12030718

APA

Woestemeier, A., Harms-Effenberger, K., Karstens, K-F., Konczalla, L., Ghadban, T., Uzunoglu, F. G., Izbicki, J. R., Bockhorn, M., Pantel, K., & Reeh, M. (2020). Clinical Relevance of Circulating Tumor Cells in Esophageal Cancer Detected by a Combined MACS Enrichment Method. CANCERS, 12(3), 718. https://doi.org/10.3390/cancers12030718

Vancouver

Woestemeier A, Harms-Effenberger K, Karstens K-F, Konczalla L, Ghadban T, Uzunoglu FG et al. Clinical Relevance of Circulating Tumor Cells in Esophageal Cancer Detected by a Combined MACS Enrichment Method. CANCERS. 2020 Mär 18;12(3):718. https://doi.org/10.3390/cancers12030718

Bibtex

@article{5aeeb8b15fc64c238c3a88960c0ec009,
title = "Clinical Relevance of Circulating Tumor Cells in Esophageal Cancer Detected by a Combined MACS Enrichment Method",
abstract = "INTRODUCTION: Current modalities to predict tumor recurrence and survival in esophageal cancer are insufficient. Even in lymph node-negative patients, a locoregional and distant relapse is common. Hence, more precise staging methods are needed. So far, only the CellSearch system was used to detect circulating tumor cells (CTC) with clinical relevance in esophageal cancer patients. Studies analyzing different CTC detection assays using advanced enrichment techniques to potentially increase the sensitivity are missing.METHODS: In this single-center, prospective study, peripheral blood samples from 90 esophageal cancer patients were obtained preoperatively and analyzed for the presence of CTCs by Magnetic Cell Separation (MACS) enrichment (combined anti-cytokeratin and anti-epithelial cell adhesion molecules (EpCAM)), with subsequent immunocytochemical staining. Data were correlated with clinicopathological parameters and patient outcomes.RESULTS: CTCs were detected in 25.6% (23/90) of the patients by combined cytokeratin/EpCAM enrichment (0-150 CTCs/7.5 mL). No significant correlation between histopathological parameters and CTC detection was found. Survival analysis revealed that the presence of more than two CTCs correlated with significantly shorter overall survival (OS) and progression-free survival (PFS).CONCLUSION: With the use of cytokeratin as an additional enrichment target, the CTC detection rate in esophageal cancer patients can be elevated and displays the heterogeneity of cytokeratin (CK) and EpCAM expression. The presence of >2CTCs correlated with a shorter relapse-free and overall survival in a univariate analysis, but not in a multivariate setting. Moreover, our results suggest that the CK7/8+/EpCAM+ or CK7/8+/EpCAM- CTC subtype does not lead to an advanced tumor staging tool in non-metastatic esophageal cancer (EC) patients.",
author = "Anna Woestemeier and Katharina Harms-Effenberger and Karl-F Karstens and Leonie Konczalla and Tarik Ghadban and Uzunoglu, {Faik G} and Izbicki, {Jakob R} and Maximilian Bockhorn and Klaus Pantel and Matthias Reeh",
year = "2020",
month = mar,
day = "18",
doi = "10.3390/cancers12030718",
language = "English",
volume = "12",
pages = "718",
journal = "CANCERS",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "3",

}

RIS

TY - JOUR

T1 - Clinical Relevance of Circulating Tumor Cells in Esophageal Cancer Detected by a Combined MACS Enrichment Method

AU - Woestemeier, Anna

AU - Harms-Effenberger, Katharina

AU - Karstens, Karl-F

AU - Konczalla, Leonie

AU - Ghadban, Tarik

AU - Uzunoglu, Faik G

AU - Izbicki, Jakob R

AU - Bockhorn, Maximilian

AU - Pantel, Klaus

AU - Reeh, Matthias

PY - 2020/3/18

Y1 - 2020/3/18

N2 - INTRODUCTION: Current modalities to predict tumor recurrence and survival in esophageal cancer are insufficient. Even in lymph node-negative patients, a locoregional and distant relapse is common. Hence, more precise staging methods are needed. So far, only the CellSearch system was used to detect circulating tumor cells (CTC) with clinical relevance in esophageal cancer patients. Studies analyzing different CTC detection assays using advanced enrichment techniques to potentially increase the sensitivity are missing.METHODS: In this single-center, prospective study, peripheral blood samples from 90 esophageal cancer patients were obtained preoperatively and analyzed for the presence of CTCs by Magnetic Cell Separation (MACS) enrichment (combined anti-cytokeratin and anti-epithelial cell adhesion molecules (EpCAM)), with subsequent immunocytochemical staining. Data were correlated with clinicopathological parameters and patient outcomes.RESULTS: CTCs were detected in 25.6% (23/90) of the patients by combined cytokeratin/EpCAM enrichment (0-150 CTCs/7.5 mL). No significant correlation between histopathological parameters and CTC detection was found. Survival analysis revealed that the presence of more than two CTCs correlated with significantly shorter overall survival (OS) and progression-free survival (PFS).CONCLUSION: With the use of cytokeratin as an additional enrichment target, the CTC detection rate in esophageal cancer patients can be elevated and displays the heterogeneity of cytokeratin (CK) and EpCAM expression. The presence of >2CTCs correlated with a shorter relapse-free and overall survival in a univariate analysis, but not in a multivariate setting. Moreover, our results suggest that the CK7/8+/EpCAM+ or CK7/8+/EpCAM- CTC subtype does not lead to an advanced tumor staging tool in non-metastatic esophageal cancer (EC) patients.

AB - INTRODUCTION: Current modalities to predict tumor recurrence and survival in esophageal cancer are insufficient. Even in lymph node-negative patients, a locoregional and distant relapse is common. Hence, more precise staging methods are needed. So far, only the CellSearch system was used to detect circulating tumor cells (CTC) with clinical relevance in esophageal cancer patients. Studies analyzing different CTC detection assays using advanced enrichment techniques to potentially increase the sensitivity are missing.METHODS: In this single-center, prospective study, peripheral blood samples from 90 esophageal cancer patients were obtained preoperatively and analyzed for the presence of CTCs by Magnetic Cell Separation (MACS) enrichment (combined anti-cytokeratin and anti-epithelial cell adhesion molecules (EpCAM)), with subsequent immunocytochemical staining. Data were correlated with clinicopathological parameters and patient outcomes.RESULTS: CTCs were detected in 25.6% (23/90) of the patients by combined cytokeratin/EpCAM enrichment (0-150 CTCs/7.5 mL). No significant correlation between histopathological parameters and CTC detection was found. Survival analysis revealed that the presence of more than two CTCs correlated with significantly shorter overall survival (OS) and progression-free survival (PFS).CONCLUSION: With the use of cytokeratin as an additional enrichment target, the CTC detection rate in esophageal cancer patients can be elevated and displays the heterogeneity of cytokeratin (CK) and EpCAM expression. The presence of >2CTCs correlated with a shorter relapse-free and overall survival in a univariate analysis, but not in a multivariate setting. Moreover, our results suggest that the CK7/8+/EpCAM+ or CK7/8+/EpCAM- CTC subtype does not lead to an advanced tumor staging tool in non-metastatic esophageal cancer (EC) patients.

U2 - 10.3390/cancers12030718

DO - 10.3390/cancers12030718

M3 - SCORING: Journal article

C2 - 32197486

VL - 12

SP - 718

JO - CANCERS

JF - CANCERS

SN - 2072-6694

IS - 3

ER -